Hydration Pharmaceuticals Announces Capital Raising and Leadership Changes
Key points
- Firm commitment to raise A$392k via placement
- Appointment of two new Non-Executive Directors
- CEO resignation with consultancy services to ensure smooth transition
Full summary
The Hydration Pharmaceuticals Company Ltd (ASX: HPC) announced a capital raising initiative to issue 98 million new shares at $0.004 each, aiming to raise A$392k. Funds will support sales momentum in the US and working capital. The company also plans to issue 49 million options at $0.006 per option, subject to shareholder approval. Additionally, the company has appointed two new Non-Executive Directors and will reduce Board remuneration by 50%. The CEO, Oliver Baker, will resign but continue as a consultant. Emily Lease will take over as General Manager.
Guidance
Capital raising of A$392k expected to complete by 17 June 2026
Outlook
Expected improvement in operating cashflow performance from 3QFY26, with ongoing exploration of strategic M&A opportunities.
Summary generated by a large language model. Please interpret with care.